Elastrin Therapeutics is developing targeted therapeutics that restore damaged elastin fibers in cardiovascular tissues, addressing issues such as arterial stiffness and hypertension. Their proprietary platform selectively delivers drugs to reverse calcification and improve vascular elasticity, potentially benefiting millions affected by cardiovascular disease.
Funding
$19.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cardiovascular disease affects a significant portion of the adult population, with a substantial number of individuals not having their conditions adequately managed. Damaged elastin fibers contribute to arterial wall weakening, leading to aortic stiffening, aneurysms, and hypertension. Current treatments primarily manage the symptoms of these conditions rather than addressing the underlying cause of elastin degradation.
Solution
Elastrin Therapeutics is developing targeted therapeutics designed to restore damaged elastin fibers in cardiovascular tissues, thereby reversing the effects of elastin degradation. Their proprietary platform enables the selective delivery of drugs to areas with damaged elastin, aiming to decalcify tissues and improve vascular elasticity. By targeting the root cause of cardiovascular issues like arterial stiffness and hypertension, Elastrin Therapeutics seeks to provide a disease-modifying treatment option. Preclinical studies have demonstrated proof of concept in animal models of cardiovascular calcification, aneurysms, and emphysema.
Target Audience
The primary target audience includes individuals suffering from cardiovascular diseases such as arterial stiffness, hypertension, and aneurysms, as well as healthcare providers specializing in cardiology and vascular medicine.
Features
- Targeted drug delivery platform for selective treatment of damaged elastin fibers.
- Focus on reversing calcification in cardiovascular tissues.
- Development of therapeutics to improve vascular elasticity.
- Preclinical validation in animal models of cardiovascular calcification, aneurysms, and emphysema.